Contractor
THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER
- UEI
- S3GMKS8ELA16
- Parent UEI
- S3GMKS8ELA16
- Resolved by
- uei
- Confidence
- 1.000
Active from Jan 24, 2019 to Aug 6, 2026.
Recent awards
| Award | Agency | Place | First action | Current value |
|---|---|---|---|---|
| 75F40126C00055 BAA FY26C1FP7; MD ANDERSON; ONCOLOGY CENTER FOR EXCELLENCE (OCE), EVALUATING BAYESIAN EFFECTIVE SAMPLE SIZE AND DECISION CRITERIA FOR PEDIATRIC AND RARE DISEASE TRIALS | Department of Health and Human Services | TX | Aug 6, 2026 | $752,304 |
| 75N97021C00001 OPERATION AND MAINTENANCE OF THE CHIMPANZEE CARE CENTER (CCC) | Department of Health and Human Services | TX | Nov 30, 2020 | $8,683,558 |
| 75N98021D00018 NON-HUMAN PRIMATE ACQUISITION, TESTING, TRANSPORTATION AND HOUSING | Department of Health and Human Services | — | Jul 20, 2021 | — |
| 75N91019D00021 PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKERS (POP: 1/25/2019 - 1/24/2024) | Department of Health and Human Services | — | Jan 24, 2019 | — |
| 36C24524P0903 EO 14398 | Department of Veterans Affairs | TX | Jun 30, 2026 | $1,147,040 |
| 75N91024D00004 PRECLINICAL EFFICACY & INTERMEDIATE ENDPOINT BIOMARKERS IDIQ CONTRACT IN SUPPORT OF THE PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM | Department of Health and Human Services | — | May 12, 2026 | — |
| 75F40123P00335 THE PURPOSE OF THIS MODIFICATION IS TO DE-OBLIGATE FUNDS AND CLOSE OUT THE CONTRACT. | Department of Health and Human Services | TX | Jun 30, 2026 | $150,052 |
| 75R60219C00004 HSB117 C 6362 CORD BLOOD CENTER 2 (MD ANDERSON) | Department of Health and Human Services | TX | May 5, 2026 | $57,937,279 |
| 75N91023F00001 TO TITLE: FURTHER DEVELOPMENT OF IPSC-BASED VACCINE FOR COLON CANCER PREVENTION BASE IDIQ TITLE: PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS | Department of Health and Human Services | TX | May 4, 2026 | $1,293,012 |
| 36C25726P0378 RATIFICATION FOR CALIBRATION SERVICES | Department of Veterans Affairs | TX | Apr 30, 2026 | $2,763 |
| 75N91022F00001 PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS TASK ORDER TITLE: TARGETING THE PARP PATHWAY FOR THE PREVENTION OF BREAST CANCER (2022 E-01) | Department of Health and Human Services | TX | Apr 28, 2026 | $1,121,090 |
| 75N91022F00002 PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINTS BIOMARKERS TASK ORDER TITLE: TARGETING STAT3 TO PREVENT NON-SMALL CELL LUNG CANCER (NSCLC) IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE | Department of Health and Human Services | TX | Apr 8, 2026 | $1,097,981 |
| 75N91023F00002 TO TITLE: TARGETING DKK1 WITH A DNA VACCINE TO PREVENT DEVELOPMENT OF MULTIPLE MYELOMA BASE IDIQ TITLE: PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINTS BIOMARKERS | Department of Health and Human Services | TX | Mar 9, 2026 | $1,249,115 |
Sources and method
Figures on this page are computed from public federal award records. Numbers are never estimated or generated; where a figure is withheld, the reason is stated rather than filled in.
Totals sum obligations across every award attributed to this contractor. Obligations are cumulative funding actions, not the value of work delivered.
- 1Awards are attributed by Unique Entity Identifier S3GMKS8ELA16, the government's own recipient identifier, not by name matching.
- 2Award records from USAspending.gov, last refreshed Aug 10, 2026.